⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
globenewswire.com
TEVA
Teva Releases Q4 2025 Aide Memoire
globenewswire.com
TEVA
Alcohol Use Disorder: Global Market Analysis, Trends and Competition Outlook 2025-2032 - Rising Adoption of AI-Driven Predictive Analytics in Mobile Health Apps - ResearchAndMarkets.com
businesswire.com
ALKS
TEVA
VTRS
Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032
globenewswire.com
ALKS
TEVA
VTRS
RDY
SUN
Medincell publie ses résultats financiers semestriels consolidés
businesswire.com
TEVA
Medincell Publishes its Consolidated Half-Year Financial Results
businesswire.com
TEVA
ABBV
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application 1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
businesswire.com
TEVA
Le partenaire de Medincell, Teva Pharmaceuticals, annonce le dépôt auprès de la FDA américaine d’une demande d’autorisation de mise sur le marché 1 pour Olanzapine LAI (TEV‑’749 / mdc‑TJK) [...]
businesswire.com
TEVA
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
globenewswire.com
TEVA
Bronchiectasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
globenewswire.com
AMGN
AZN
GILD
TEVA